Clinical Trial Update: Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating paricalcitol on markers of inflammation in hemodialysis patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Paricalcitol (Zemplar) (paricalcitol)

Snippet

Sponsor: Fresenius Medical Care North America | Conditions: Kidney Failure | Phase 4 | Status: COMPLETED